BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Jørgensen JT. Role of human epidermal growth factor receptor 2 in gastric cancer: Biological and pharmacological aspects. World J Gastroenterol 2014; 20(16): 4526-4535 [PMID: 24782605 DOI: 10.3748/wjg.v20.i16.4526]
URL: https://www.wjgnet.com/1007-9327/full/v20/i16/4526.htm
Number Citing Articles
Amaia Eleonora Maennling, Mehmet Kemal Tur, Marcus Niebert, Torsten Klockenbring, Felix Zeppernick, Stefan Gattenlöhner, Ivo Meinhold-Heerlein, Ahmad Fawzi Hussain. Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future PotentialsCancers 2019; 11(12): 1826 doi: 10.3390/cancers11121826
J.T. Jørgensen, K.B. Nielsen. Comprehensive Medicinal Chemistry III2017; : 530 doi: 10.1016/B978-0-12-409547-2.12336-4
Sofie L. Nielsen, Søren Nielsen, Mogens Vyberg. Digital Image Analysis of HER2 Immunostained Gastric and Gastroesophageal Junction AdenocarcinomasApplied Immunohistochemistry & Molecular Morphology 2017; 25(5): 320 doi: 10.1097/PAI.0000000000000463
Hung-Man Yu, Jyun-Hong Chen, Kun-Liang Lin, Wuu-Jyh Lin. Synthesis of68Ga-labeled NOTA-RGD-GE11 heterodimeric peptide for dual integrin and epidermal growth factor receptor-targeted tumor imagingJournal of Labelled Compounds and Radiopharmaceuticals 2015; 58(7): 299 doi: 10.1002/jlcr.3296
Xinyue Zhang, Jie Yao, Kai Guo, Hu Huang, Siyuan Huai, Rui Ye, Baolong Niu, Tiannan Ji, Weidong Han, Jianxiong Li. The functional mechanism of miR-125b in gastric cancer and its effect on the chemosensitivity of cisplatinOncotarget 2018; 9(2): 2105 doi: 10.18632/oncotarget.23249
Antonio Ieni, Roberta Cardia, Cristina Pizzimenti, Pio Zeppa, Giovanni Tuccari. HER2 Heterogeneity in Personalized Therapy of Gastro-Oesophageal Malignancies: An Overview by Different MethodologiesJournal of Personalized Medicine 2020; 10(1): 10 doi: 10.3390/jpm10010010
Federico Coccolini, Giulia Montori, Marco Ceresoli, Simona Cima, Maria Carla Valli, Gabriela E Nita, Arianna Heyer, Fausto Catena, Luca Ansaloni. Advanced gastric cancer: What we know and what we still have to learnWorld Journal of Gastroenterology 2016; 22(3): 1139-1159 doi: 10.3748/wjg.v22.i3.1139
Tasuku Matsuoka, Masakazu Yashiro. Recent advances in the HER2 targeted therapy of gastric cancerWorld Journal of Clinical Cases 2015; 3(1): 42-51 doi: 10.12998/wjcc.v3.i1.42
Andrew S. Dixon, Sun Jin Kim, Brett K. Baumgartner, Sylvia Krippner, Shawn C. Owen. A Tri-part Protein Complementation System Using Antibody-Small Peptide Fusions Enables Homogeneous ImmunoassaysScientific Reports 2017; 7(1) doi: 10.1038/s41598-017-07569-y
Giuseppe Tridente. Adverse Events and Oncotargeted Kinase Inhibitors2017; : 243 doi: 10.1016/B978-0-12-809400-6.00011-1
Mayuko Saito, Kentaro Yamashita, Yoshiaki Arimura, Hiroyuki Kaneto, Hiroyuki Okuda, Masanori Nojima, Takeshi Hagiwara, Kazuya Suzuki, Takeya Adachi, Akira Goto, Kohei Nakachi, Atsushi Yawata, Mitsuru Yoshimoto, Tokuma Tanuma, Yasushi Adachi, Satoshi Yamaoka, Tsunenori Mizukoshi, Mariko Kawayama, Yasuo Hamamoto, Yasuhisa Shinomura. Serum HER2 as an adjunct to assess HER2 status for advanced gastric cancer: A prospective multicenter trial (SHERLOCK)Acta Oncologica 2016; 55(3): 309 doi: 10.3109/0284186X.2015.1107189
Yongfeng Ding, Yanyan Chen, Mengjie Wu, Linrong Li, Yingying Huang, Haiyong Wang, Haohao Wang, Xiongfei Yu, Nong Xu, Lisong Teng. Identification of genes associated with gastric cancer survival and construction of a nomogram to improve risk stratification for patients with gastric cancerOncology Letters 2020;  doi: 10.3892/ol.2020.11543
MIAOLIN ZHU, XIAOYUAN YAO, MIN WU, HAI QIAN, YAN WU, YONGCHANG CHEN. Type II cGMP-dependent protein kinase directly inhibits HER2 activation of gastric cancer cellsMolecular Medicine Reports 2016; 13(2): 1909 doi: 10.3892/mmr.2015.4688
Jonathan Cools-Lartigue, Laura Baker, Lorenzo E. Ferri. Gastric Cancer2015; : 35 doi: 10.1007/978-3-319-15826-6_3
Felice Pasini, Anna Paola Fraccon, Yasmina Modena, Maria Bencivenga, Simone Giacopuzzi, Francesca La Russa, Milena Gusella, Giovanni de Manzoni. Targeted therapies for advanced and metastatic adenocarcinoma of the gastroesophageal junction: is there something new?Gastric Cancer 2017; 20(1): 31 doi: 10.1007/s10120-016-0626-0
Catalin Bogdan Satala, Ioan Jung, Raluca Ioana Stefan-van Staden, Zsolt Kovacs, Calin Molnar, Tivadar Bara, Zsolt Zoltan Fulop, Simona Gurzu, Nicola Silvestris. HER2 Heterogeneity in Gastric Cancer: A Comparative Study, Using Two Commercial AntibodiesJournal of Oncology 2020; 2020: 1 doi: 10.1155/2020/8860174
H.-T. Arkenau, A. Italiano, G. Mak, M. Toulmonde, R.D. Baird, J. Garcia-Corbacho, R. Plummer, M. Flynn, M. Forster, R.H. Wilson, D. Tosi, A. Adenis, K. Donaldson, J. Posner, I. Kawabata, A. Arimura, S. Deva, J. Spicer. An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumoursEuropean Journal of Cancer 2018; 103: 17 doi: 10.1016/j.ejca.2018.07.134
Jan Trøst Jørgensen, Henrik Winther, Jon Askaa, Lena Andresen, Dana Olsen, Jens Mollerup. A Companion Diagnostic With Significant Clinical Impact in Treatment of Breast and Gastric CancerFrontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.676939
Mitsuro Kanda, Yasuhiro Kodera, Junichi Sakamoto. Updated evidence on adjuvant treatments for gastric cancerExpert Review of Gastroenterology & Hepatology 2015; 9(12): 1549 doi: 10.1586/17474124.2015.1094373
Chien-Jen Chen, Chen-Hsin Chan, Kun-Liang Lin, Jyun-Hong Chen, Chun-Hao Tseng, Ping-Yen Wang, Chuan-Yi Chien, Hung-Man Yu, Wuu-Jyh Lin. 68Ga-labelled NOTA-RGD-GE11 peptide for dual integrin and EGFR-targeted tumour imagingNuclear Medicine and Biology 2019; : 22 doi: 10.1016/j.nucmedbio.2018.11.003
A. Marcell Szász, András Lánczky, Ádám Nagy, Susann Förster, Kim Hark, Jeffrey E. Green, Alex Boussioutas, Rita Busuttil, András Szabó, Balázs Győrffy. Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patientsOncotarget 2016; 7(31): 49322 doi: 10.18632/oncotarget.10337
Naoki Takahashi, Koh Furuta, Hirokazu Taniguchi, Yusuke Sasaki, Hirokazu Shoji, Yoshitaka Honma, Satoru Iwasa, Natsuko Okita, Atsuo Takashima, Ken Kato, Tetsuya Hamaguchi, Yasuhiro Shimada, Yasuhide Yamada. Serum level of hepatocyte growth factor is a novel marker of predicting the outcome and resistance to the treatment with trastuzumab in HER2-positive patients with metastatic gastric cancerOncotarget 2016; 7(4): 4925 doi: 10.18632/oncotarget.6753
Gaetano Romano. Tumor markers currently utilized in cancer careMaterials and Methods 2015; 5 doi: 10.13070/mm.en.5.1456
Alexandra Thiel, Ari Ristimäki. Targeted therapy in gastric cancerAPMIS 2015; 123(5): 365 doi: 10.1111/apm.12359
G Jomrich, SF Schoppmann. Targeting HER 2 and angiogenesis in gastric cancerExpert Review of Anticancer Therapy 2016; 16(1): 111 doi: 10.1586/14737140.2016.1121110
Rameez Hasan, Deepti Bhatt, Shahbaz Khan, Vasiuddin Khan, Amit Kumar Verma, Prahalad Singh Bharti, Afzal Anees, Kapil Dev. Frequency of I655V SNP of HER-2/neu in colorectal cancer: a study from India3 Biotech 2019; 9(1) doi: 10.1007/s13205-018-1545-z
Jingyue Sun, Yao Long, Xin Peng, Desheng Xiao, Jianhua Zhou, Yongguang Tao, Shuang Liu. The survival analysis and oncogenic effects of CFP1 and 14-3-3 expression on gastric cancerCancer Cell International 2019; 19(1) doi: 10.1186/s12935-019-0946-3
Robert Roskoski. ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitorsPharmacological Research 2014; 87: 42 doi: 10.1016/j.phrs.2014.06.001
Roberto Carmagnani Pestana, Shiraj Sen, Brian P. Hobbs, David S. Hong. Histology-agnostic drug development — considering issues beyond the tissueNature Reviews Clinical Oncology 2020; 17(9): 555 doi: 10.1038/s41571-020-0384-0